US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Diagonal Bio enters into a strategic partnership with Daniel Redén at StallZet to enhance commercialisation plans

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces that Daniel Redén, a renowned horse trainer at StallZet, has entered into a partnership with Diagonal Bio and will act as a marketing partner for the Company to enhance the commercialisation plans for the Company’s platform, LAMPlify®️. StallZet, one of Sweden's leading trotting facilities with over 190 horses, is collaborating with Diagonal Bio in the ongoing pilot test of LAMPlify®️. As a marketing partner to Diagonal Bio, Daniel Redén will play a key role in showcasing the benefits of LAMPlify® and promoting the product.

Read original

Renowned horse race jockey and trainer conducts pilot test of LAMPlify®

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces that one of Sweden’s most accomplished horse race trainers, Madeleine Smith, has initiated a six-month pilot test of LAMPlify®.  The pilot test will focus on enhancing equine health and performance through early detection of potential respiratory viruses in horses. The test will be conducted via Madeleine Smith's horse race training operation M. Smith Galopp.Based at Bro Park, Madeleine Smith is a highly accomplished jockey and horse race trainer with over 500 wins as a jockey and 300 victories as a trainer. Her stable, M.

Read original

Nomination Committee appointed for Diagonal Bio

Diagonal Bio today announces that the Nomination Committee has been appointed in preparation for the Annual General Meeting (AGM) on May 20, 2025.According to the instruction for the Nomination Committee adopted by the AGM in 2024, the Nomination Committee for the Diagonal Bios AGM 2025 shall consist of four members, representing the three largest shareholders on September 30th together with the Chairman of the Board. If a shareholder does not exercise its right to appoint a member, entitlement to appoint a member of the Nomination Committee transfers to the shareholder who is the next

Read original

Diagonal Bio announces pilot test with LAMPlify® at Kolgjini Stables

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces a partnership with Kolgjini Stables (Stall Kolgjini), founded by renowned harness racer Lutfi Kolgjini, to conduct a three-month pilot test. Kolgjini Stables is a Swedish stable known for its expertise in growing horses for both breeding and for top-tier national and international competition. This pilot test starts immediately and aims to evaluate the potential of the LAMPlify® platform to provide rapid and accurate virus detection in horses.Kolgjini Stables, led by Lutfi Kolgjini, is a prominent player both in harness

Read original

Diagonal Bio announces that it is exploring financing options

Diagonal Bio AB ("Diagonal Bio" or "the Company") today announces that the Board of Directors of the Company has engaged financial and legal advisors and decided to explore potential financing alternatives to secure the Company’s ongoing operations and support its strategic goals. The current funds last until mid-February 2025.Diagonal Bio is in discussions with strategic investors and several of its larger shareholders regarding possible solutions to address the Company’s liquidity situation. In addition, the Company has engaged a financial advisor as well as a legal advisor to assist in

Read original

Diagonal announces first pilot test at a stud with LAMPlify®

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces a partnership with Gocksta Stud (Gocksta Stuteri), led by Anne-Sophie Thiam, to conduct a three-month pilot study, which begins immediately. This pilot test will evaluate LAMPlify’s potential for rapid detection of respiratory viruses in horses, with a specific focus on EHV1 (equine herpesvirus type 1). This virus poses a significant risk in horse breeding due to its potential to cause spontaneous abortion in pregnant mares.Anne-Sophie Thiam, the founder and owner of the stud, oversees between 40–60 mares annually at her

Read original

Diagonal Bio AB Third Quarter Report (Q3 2024)

“One of the most exciting developments is our effort into a new application of our technology LAMPlify®—this time in the domain of swine diseases.”Summary of Q3 report 2024 2024-07-01 — 2024-09-30 (July — September 2024) ●         Net sales amounted to 0 KSEK (0 KSEK), capitalised development contributedwith 248 KSEK (781 KSEK), and other operating income amounted to 0 KSEK (8 KSEK). ●         Operating profit amounted to -1 242 KSEK (-2 605 KSEK). ●         Operating profit per net weighted average share amounted to 0 SEK (-0.08 SEK). ●         Cash flow during the third

Read original

Diagonal Bio announces pilot test of LAMPlify® at Norwegian University of Life Sciences

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces the commencement of a six-month pilot test of its point-of-care diagnostic platform, LAMPlify®, at the Norwegian University of Life Sciences (NMBU) in Ås. The pilot, which will be conducted in collaboration with the Faculty of Veterinary Medicine and Biosciences, specifically the Department of Companion Animal Clinical Sciences, aims to evaluate the effectiveness and potential integration of LAMPlify® within the university's equine hospital.The veterinary team at NMBU, led by Associate Professor Ingunn Risnes Hellings, will

Read original

Diagonal Bio will present LAMPlify® at a partnered event for trainers at Jägersro

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") will be participating in a partnered event with Svensk Galopp, at Jägersro on November 7, 2024. The Company’s diagnostic platform, LAMPlify®, will be introduced to a select group of invited trainers.During the evening, Diagonal Bio will provide insights into recent test results from the collaboration with University of Copenhagen (UCPH). In addition, Diagonal Bio will showcase the functionality of LAMPlify® through a live demonstration, giving attendees a firsthand look at its capabilities and potential applications. Approximately

Read original

Diagonal Bio announces successful external validation of LAMPlify® for viruses in pigs

Diagonal Bio AB (publ) (“Diagonal” or “the Company”) announces successful results of a recent pilot study conducted by the Centre for Diagnostics at DTU Health Technology. The study evaluated the performance of the LAMPlify® assay panel for tests specific to Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) type 1 and type 2, and Swine Influenza Virus (SIV), by comparing it to the gold-standard PCR (qPCR) tests.The study showed excellent agreement between the LAMPlify® assays and qPCR tests, yielding identical positive/negative classifications between the methods. The samples were

Read original

Hunneberga Horse Stable to conduct pilot test of LAMPlify®

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces that Hunneberga Horse Stable (Hunneberga Hästgård) and Tomas Hammar, showjumping trainer and CEO at Hunneberga Horse Stable, has initiated a partnership with Diagonal Bio to conduct a pilot test. The agreement is set to three months and will involve a testing program of LAMPlify® to detect respiratory viral infections in showjumping horses during upcoming competitions. The pilot will start immediately.Tomas Hammar, responsible for 20 competition horses and actively participating in both national and international events,

Read original

Horse trainer Daniel Redén at StallZet will conduct a pilot with LAMPlify®

Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) has partnered with StallZet and Daniel Redén, one of Sweden's leading horse trotting training facilities, to conduct a pilot test using LAMPlify® to detect respiratory viral infections in StallZet’s trotters. The three-month agreement takes effect immediately.The pilot test is set to provide faster and more accurate, point-of-care diagnostics, potentially leading to quick action to increase the well-being of StallZet’s trot training facility. StallZet manages over 190 horses and has a vast national and international network in the

Read original

Diagonal Bio AB’s warrant exercise registered at the Swedish Companies Registration Office

Diagonal Bio AB ("Diagonal" or the "Company") today announces that the new shares from the exercise of warrants of series TO 1 have been registered with the Swedish Companies Registration Office.On 26 September 2024, the exercise period for warrants of series TO 1, which were issued in connection with Diagonal’s rights issue of units earlier in 2024, ended. As a result of the warrant exercise, 77.794 new shares have now been registered with the Swedish Companies Registration Office. The total number of shares in the Company after the exercise of warrants of series TO 1 amount to 400.714.213

Read original

Diagonal Bio AB announces the outcome of the exercise of warrants of series TO 1

On September 26, 2024, the exercise period for Diagonal Bio AB's ("Diagonal" or the "Company") warrants of series TO 1 ("TO 1") ended. A total of 77.794 warrants of series TO 1 have been exercised to subscribe for 77.794 shares, corresponding to gross proceeds of SEK 3.889,70.During the exercise period from and including September 12, 2024, up to and including September 26, 2024, holders of warrants of series TO 1 have had the right to subscribe for one (1) new share in Diagonal for each warrant of series TO 1 at a price of SEK 0,05 per share. A total of 77.794 warrants of series TO 1 have

Read original

The last day of trading in warrants of series TO 1 is on the 24th of September 2024

The 24th of September 2024 is the last day of trading in warrants of series TO 1, which were issued in connection with Diagonal Bio AB's ("Diagonal Bio" or the "Company") preferential rights issue of units that was carried out earlier in 2024. The exercise period runs until the 26th of September 2024.In connection with the Company's preferential rights issue of units carried out earlier in 2024, 45.082.580 warrants of series TO 1 were issued. Holders of TO 1 have the right to subscribe for one (1) new share in Diagonal Bio at a price of SEK 0,05 per share during the exercise period, which

Read original

The exercise period for warrants of series TO 1 commences today

Today is the first day for the exercise of Diagonal Bio AB's ("Diagonal Bio" or "the Company") warrants of series TO 1 ("TO 1") which were issued in connection with the preferential issue of units that the Company carried out earlier this year. The period lasts until June 26, 2024. Holders of TO 1 have the right to subscribe for one (1) new share in Diagonal Bio for each TO 1 at a price of SEK 0,05 per share. Through full utilisation of TO 1, the Company will receive approximately SEK 2,25 million before issue costs. An information document is available on the respective websites of Diagonal

Read original

The exercise price for warrants of series TO 1 has been set to SEK 0,05 per new share

Diagonal Bio AB ("Diagonal Bio" or "the Company") hereby announces that the exercise price for the warrants of series TO 1 (”TO 1”), which were issued in connection with the rights issue of units that the Company executed earlier during 2024, has been set. The exercise price for TO 1 has been set to SEK 0,05 per share and the exercise period commences on September 12, 2024.In April 2024, Diagonal Bio carried out a rights issue which brought the Company approximately SEK 18 million before issue costs. Through the rights issue, 45.082.580 warrants of series TO 1 were issued. Each TO 1

Read original

Diagonal Bio announces successful external validation of LAMPlify® for respiratory viruses in horses

Diagonal Bio AB (publ) (“Diagonal Bio” and “the Company”) announces that its diagnostic tool, LAMPlify® has undergone a successful external validation in accordance with ISO 17025 standards. It is confirming that LAMPlify® is as reliable as established real-time PCR (qPCR) methods for the detection of respiratory viruses in horses, including equine herpesvirus 1 (EHV-1) and equine herpesvirus 4 (EHV-4).The recent validation study focused on evaluating the performance of LAMPlify® to detect EHV-1 and EHV-4 in horses. The study was conducted by the Department of Veterinary and Animal Sciences,

Read original

Diagonal Bio AB Second Quarter Report (Q2 2024)

“In the second quarter of 2024, we have made advancements, particularly within the equine healthcare sector (horse veterinary clinics) where our connections and the interest in our Point-of-Care instrument continue to deepen.”Summary of Q1 report 2024 2024-04-01 — 2024-06-30 (April — June 2024) ●         Net sales amounted to 0 KSEK (0 KSEK), capitalised development contributed with 284 KSEK (911 KSEK),and other operating income amounted to 0 KSEK (4 KSEK). ●         Operating profit amounted to -3 118 KSEK (-2 798 KSEK). ●         Operating profit per net weighted average

Read original

Diagonal Bio receives order from the Technical University of Denmark

Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) has secured an order from the Technical University of Denmark (“DTU”) valued at just over 210,000 SEK for fish farms’ health project HURTIGFISK. The order includes supply of Diagonal Bios diagnostic instrument LAMPlify®, consumables and consulting services. The project aims to revolutionise monitoring of fish farm diseases, by point-of-care diagnostics.The Technical University of Denmark (DTU) and Copenhagen University (KU) has received funding for a fish health project, HURTIGFISK, a project which is a part of KU's efforts to advance

Read original

Bulletin from the Annual General Meeting on 11 June 2024 in Diagonal Bio AB

Today, on 11 June 2024, the Annual General Meeting of Diagonal Bio AB was held. A summary of the adopted resolutions follows below.Resolution on adoption of the accounts and appropriation of profit The Annual General Meeting resolved to adopt the income statement and the balance sheet. The Annual General Meeting also resolved to dispose of the company’s profit in accordance with the board’s proposal, meaning that no dividend will be paid and that available funds will be carried forward. Discharge from liability for the members of the board of the directors and the CEO The Annual

Read original

Diagonal Bio AB first quarter (Q1 2024)

“The end of last year was marked by our focus on creating the business platform to generate the company's initial revenue in 2024. We continue and gear up on the set path with a focus on generating revenue”.Summary of Q1 report 2024 2024-01-01 — 2024-03-31 (January — March 2024) • Net sales amounted to 0 KSEK (0 KSEK), capitalised development contributed with 250 KSEK (1 030 KSEK), and other operating income amounted to 5 KSEK (6 KSEK). • Operating profit amounted to -2 727 KSEK (-3 701 KSEK). • Operating profit per net weighted average share amounted to -0.07 SEK (-0.11 SEK).

Read original

Diagonal Bio appoints new CFO

Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) has appointed Fata Mrsic as the new Chief Financial Officer (CFO). Fata will assume the position on June 14, 2024, and be part of the Management Team.Fata Mrsic has extensive financial and accounting experience. She has held Business Controller and Accounting positions at several companies in the past 15 years, some with global presence. Fata has a Diploma in Business Controlling from the University of Lund.   “We welcome Fata Mrsic as our new CFO. Fata knows our company well already since she started as Business Controller in

Read original
There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe